Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial-Reference-Cited by-同舟云学术

Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial

Published:2018-12-22 Issue:19 Volume:40 Page:1518-1527
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Chao Tze-Fan¹²,Chen Shih-Ann¹²,Ruff Christian T³,Hamershock Rose A³,Mercuri Michele F⁴,Antman Elliott M³,Braunwald Eugene³,Giugliano Robert P³

Affiliation:

1. Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Rd., Beitou District, Taipei City 112, Taiwan

2. Institute of Clinical Medicine, and Cardiovascular Research Center, National Yang-Ming University, No. 155, Sec. 2, Linong St., Beitou District, Taipei City 112, Taiwan

3. Division of Cardiovascular Medicine, TIMI Study Group, Brigham and Women’s Hospital, 60 Fenwood Road, 7th Floor, Suite 7022, Boston, MA, USA

4. Cardiovascular, Metabolic and Renal Disease Therapeutic Area, Global Clinical Development, Daiichi Sankyo Pharma Development, 211 Mt. Airy Road, Basking Ridge, NJ USA

Funder

Daiichi Sankyo Pharma Development

Brigham and Women’s Hospital

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/article-pdf/40/19/1518/28604424/ehy807.pdf

Reference26 articles.

1. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation;Hori;Stroke,2013

2. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial;Wong;Stroke,2014